Guardant Health (GH) Trading Down 6.4%
Shares of Guardant Health Inc (NASDAQ:GH) were down 6.4% on Wednesday . The stock traded as low as $71.05 and last traded at $71.50. Approximately 1,186,877 shares were traded during trading, an increase of 18% from the average daily volume of 1,002,726 shares. The stock had previously closed at $76.38.
GH has been the topic of several research analyst reports. Canaccord Genuity initiated coverage on Guardant Health in a research report on Tuesday, April 16th. They set a “buy” rating and a $90.00 price target on the stock. Bank of America upgraded Guardant Health from a “neutral” rating to a “buy” rating and set a $84.00 price target on the stock in a research report on Wednesday, April 10th. William Blair reiterated an “outperform” rating on shares of Guardant Health in a research report on Wednesday, March 13th. Cowen lifted their price target on Guardant Health from $40.00 to $70.00 and gave the company an “outperform” rating in a research report on Wednesday, April 3rd. Finally, JPMorgan Chase & Co. lifted their price target on Guardant Health from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Friday, May 10th. One research analyst has rated the stock with a sell rating and six have given a buy rating to the company. The stock presently has an average rating of “Buy” and an average price target of $83.50.
The stock has a market cap of $6.60 billion and a PE ratio of -27.50.
In related news, Chairman Amirali Talasaz sold 232,460 shares of Guardant Health stock in a transaction on Monday, April 22nd. The stock was sold at an average price of $65.60, for a total value of $15,249,376.00. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Vision Fund (Aiv M1) Softbank bought 2,033,990 shares of the firm’s stock in a transaction that occurred on Tuesday, March 12th. The stock was bought at an average price of $9.83 per share, for a total transaction of $19,994,121.70. The disclosure for this purchase can be found here. Over the last quarter, insiders have sold 975,338 shares of company stock worth $66,706,026.
Several hedge funds and other institutional investors have recently modified their holdings of GH. First Trust Advisors LP grew its holdings in shares of Guardant Health by 0.4% during the first quarter. First Trust Advisors LP now owns 71,871 shares of the company’s stock valued at $5,513,000 after buying an additional 264 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of Guardant Health by 1.8% during the first quarter. Rhumbline Advisers now owns 20,247 shares of the company’s stock valued at $1,553,000 after buying an additional 367 shares in the last quarter. Financial Advocates Investment Management grew its holdings in shares of Guardant Health by 24.9% during the first quarter. Financial Advocates Investment Management now owns 2,785 shares of the company’s stock valued at $214,000 after buying an additional 555 shares in the last quarter. Northern Trust Corp grew its holdings in shares of Guardant Health by 0.3% during the first quarter. Northern Trust Corp now owns 194,666 shares of the company’s stock valued at $14,931,000 after buying an additional 571 shares in the last quarter. Finally, Benjamin F. Edwards & Company Inc. purchased a new position in shares of Guardant Health during the fourth quarter valued at $26,000. Institutional investors and hedge funds own 66.99% of the company’s stock.
TRADEMARK VIOLATION WARNING: This piece was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was illegally stolen and reposted in violation of US & international trademark and copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/guardant-health-gh-trading-down-6-4/3021380.html.
About Guardant Health (NASDAQ:GH)
Guardant Health, Inc, a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers liquid biopsy tests for advanced stage cancer, such as Guardant360, a molecular diagnostic test that measures various cancer-related genes; and GuardantOMNI, a broader gene panel, including genes associated with homologous recombination repair deficiency and biomarkers for immuno-oncology applications.
Featured Story: How to Profit and Limit Losses With Stop Orders
Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.